Argo Blockchain
ARBK
BTCS Inc
BTCS
Canaan
CAN
Bit Origin
BTOG
Bitfarms
BITF
US Stock MarketDetailed Quotes
LXEO Lexeo Therapeutics
- 4.500
- +0.280+6.64%
Close Feb 14 16:00 ET
- 4.550
- +0.050+1.11%
Post 20:01 ET
148.80MMarket Cap-1.72P/E (TTM)
4.575High4.260Low252.80KVolume4.560Open4.220Pre Close1.12MTurnover1.36%Turnover RatioLossP/E (Static)33.07MShares19.50052wk High1.07P/B83.87MFloat Cap3.84052wk Low--Dividend TTM18.64MShs Float22.330Historical High--Div YieldTTM7.46%Amplitude3.840Historical Low4.435Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Lexeo Therapeutics Stock Forum
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints
Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling...
NEWS
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
No comment yet